COMPEL: Chemotherapy with/without Osimertinib in Patients with EGFRm advanced NSCLC and Progression on first-line Osimertinib

Introduction Osimertinib is the preferred first-line (1L) treatment in EGFRm advanced NSCLC. Guidelines recommend discontinuing osimertinib upon systemic progression and initiating platinum-based doublet chemotherapy (CT). Continuation of osimertinib during CT may be beneficial compared with CT alone, particularly in patients with CNS metastases, and it may prevent rebound phenomenon due to tumour heterogeneity. COMPEL (NCT04765059) will evaluate efficacy and safety of CT+osimertinib versus CT+placebo in patients (pts) with EGFRm advanced NSCLC who experienced non-CNS progression following 1L osimertinib therapy.